The importance of the immune system in the response to KRAS-G12C inhibition was revealed when Canon et al. (6) showed that T cell presence was essential for durable responses in subcutaneous tumors of the colon cancer model CT26 treated with sotorasib. Here, KRAS is linked to malignant colon neoplasm.